{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.1","upperLimit":"12.3","value":"2.3"},{"groupId":"OG001","lowerLimit":"1.4","upperLimit":"18.3","value":"6.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"},{"groupId":"OG001","value":"45"}],"units":"Participants"}],"description":"CR was defined as negative IFE on the serum and urine and disappearance of any soft tissue plasmacytomas and ≤5% plasma cells in bone marrow aspirates based on Investigator assessment per IMWG response criteria. Data are reported for the percentage of participants with CR or better.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with anti-CD38 mAb-naive RRMM received daratumumab at a dose of 1,800 mg by subcutaneous (SC) injection in 28-day treatment cycles.","id":"OG000","title":"RRMM Expansion Part B: Daratumumab"},{"description":"Participants with anti-CD38 mAb-naive RRMM received GEN3014 IV infusion at a dose of 16 mg/kg in 28-day treatment cycles.","id":"OG001","title":"RRMM Expansion Part B: GEN3014"}],"paramType":"NUMBER","populationDescription":"Full Analysis set included all enrolled participants who received at least 1 dose of trial drug (GEN3014 or daratumumab SC). Overall number of participants analyzed=participants evaluable for the outcome measure.","reportingStatus":"POSTED","timeFrame":"Up to approximately 4 years 3 months","title":"Expansion Part B: Percentage of Participants With Complete Response (CR) or Better","type":"SECONDARY","unitOfMeasure":"percentage of participants"}